Diabetes PubMed

In this community-based cohort, 30 months of therapy with rosiglitazone treatment was associated with increased risk of congestive heart failure (CHF) but was not associated with increased risk of acute myocardial infarction (AMI), acute coronary syndrome (ACS), coronary revascularization, or all-cause mortality.

Rosiglitazone may protect against cognitive decline in older persons with type 2 diabetes and mild cognitive impairment (MCI).

Disclosure rates for financial conflicts of interest were unexpectedly low, and there was a clear and strong link between the orientation of authors' expressed views on the rosiglitazone controversy and their financial conflicts of interest with pharmaceutical companies.

Given that rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of rosiglitazone may not be justified.

This study suggests that rosiglitazone treatment slows the progressive deterioration of renal function in patients with type 2 diabetes.

Therefore, rosiglitazone can be prescribed as long as the indications are followed and the patients concerned do not have heart failure or an increased risk for this.

Although the long-term sustainability of these improvements cannot be determined from the present study, these findings demonstrate that the diabetes preventive effect of rosiglitazone was in part a consequence of improved beta-cell function.

Further studies are needed to elucidate the insulin sensitizing mechanism of rosiglitazone on peripheral skeletal muscles.

These results suggest that rosiglitazone monotherapy has favorable effects on arterial stiffness compared with metformin monotherapy independent of glycemic control.

Rosiglitazone plus exercise training elicited additive effects on body composition, glycemic control, and traditional and novel cardiovascular risk factors in type 2 diabetes mellitus patients, indicating complementary effects.